# Lenalidomide for Patients With Myelofibrosis (MF)

> **NCT00352794** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00352794
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-07
- **Primary completion:** 2018-03-08
- **Final completion:** 2018-03-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352794, "Lenalidomide for Patients With Myelofibrosis (MF)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00352794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*